This step does not occur to any significant 10
Non-FDA-approved indications are mucocutaneous HSV, herpes zoster (shingles), and varicella zoster (chickenpox)
The pharmacokinetics of acyclovir in children (greater than 1 year of age) are similar to those in adults
VCV is a prodrug of ACV and has improved oral bioavailability, compared to oral acyclovir [ 2 ]
Plasma protein binding is low for both molecules (15
The absence of arbon atoms at he 2'- and thus pharmacologic and pharmacokinetic studies 3'- positions make this guanosine analog incapable play a role
This study aimed to characterize the pharmacokinetics (PK) of acyclovir and its oral prodrug valacyclovir to optimize dosing in children
Acyclovir was administered as an intravenous infusion over 1 hour at a dose of 5 mg/kg daily in one patient and 10 mg/kg every 48 hours in two patients
This affliction might be induced by HSV infection requiring a treatment by acyclovir
Acyclovir pharmacokinetic parameters and exposure metrics did not correlate with either virologic or clinical response metrics in this study
After intravenous dosing of patients with normal renal function, 8 to 14% of the dose is Pharmacokinetics: Acyclovir is slowly and poorly absorbed from the gastrointestinal tract and bioavailability decreases with increasing dose
It works by blocking the enzyme that the virus needs to make its DNA
0 years, 73 males and 47 females) received IV acyclovir for prophylaxis ( n Acyclovir (Topical) Pharmacokinetics Absorption Bioavailability
Acyclovir (9- [2-hydroxymethyl]guanine) is a nucleoside analog that selectively inhibits the replication of herpes simplex virus types 1 and 2 (HSV-1, HSV-2) and varicella-zoster virus (VZV)
It shows good in vitro activity against herpes simplex and varicella-zoster viruses
e
Valacyclovir, an orally administered pro-drug of acyclovir, is utilized in the therapy of herpes simplex and herpes zoster infections
Acyclovir was well tolerated, and no toxicity was seen in the mothers or Acyclovir is a new antiviral drug that acts as a specific inhibitor of herpesvirus DNA polymerase
Pharmacokinetics of acyclovir in humans following intravenous administration
5 to 15 mg/kg (Study 2, 3, and 4) and after multiple doses ranging from 2
Acyclovir (5 mg/kg) was given as a 1-h infusion to three volunteers with normal renal function both before and after oral administration of probenecid (1 g)
305 × [postmenstrual age (PMA)/31
CONCLUSIONS Even when the acyclovir dose is properly adjusted for kidney function based on the current manufacturer's recommendations, it can cause neurotoxicity
Intravenous acyclovir is routinely used to treat herpes simplex virus (HSV) infection in preterm and term infants
2165 Here, we discuss the pharmacokinetics of acyclovir and make some recommendations with regard to dose adjustment in patients with ESRD
The study was aimed at investigating the population pharmacokinetics (POP/PK) of intravenous (IV) acyclovir in oncologic children
v
Abstract
Whiteman The Wellcome Research Laboratories, Beckenham, Kent Summary Acyclovir (ACV) has a novel, highly selective biological activity which results in the inhibition of herpesvirus replication at concentrations 3oo-3ooo-fold lower than those that Highly variable disposition after oral ingestion of acyclovir has been reported, although little is known regarding the underlying mechanisms
0 (n=13) included four groups, with GA 23-42 weeks and PNA up to 60 days; version 2
Acyclovir (ACV) has a novel, highly selective biological activity which results in the inhibition of herpesvirus replication at concentrations 300-3000-fold lower than those that will inhibit mammalian The elimination of acyclovir after oral administration was monophasic, with an apparent half-life of 1
Intravenously administered [8-14C]valaciclovir (10 mg/kg) was rapidly converted to The amino acid prodrug of acyclovir (ACV), valacyclovir (VACV), is an effective antiherpetic drug
104
Acyclovir pharmacokinetic parameters are summarized in Table 1
The aim of this study is to provide insight into the pharmacodynamics (PD) of (val)acyclovir
The current status of pharmacokinetic and toxicologic information on acyclovir is reviewed from a clinical pharmacologist's perspective